Evidence map›Paper›PMID 33057730›Full record

ArticleJournal of rehabilitation medicine2021

A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.

Gerard E Francisco, Alexander Balbert, Ganesh Bavikatte, Djamel Bensmail, Stefano Carda, Thierry Deltombe, Nathalie Draulans, Steven Escaldi, Raphael Gross, Jorge Jacinto and 9 more

Registry-linked trialAbstract readMulticenter StudyConsensus Statement
In one paragraph

Article in Journal of rehabilitation medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811142 (EVALUATION OF THE EFFECTS OF EARLY APPLICATION OF BOTULINUM TOXIN IN PATIENTS WITH A FIRST CEREBRAL VASCULAR EVENT.), which is not on this map. Cited by 52 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06811142 early_phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the effects of early application of botulinum toxin in patients with a first cerebral vascular event.

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2025 to 2030Enrolled200ConditionsSpasticity, Stroke, Neurological RehabilitationArmsBotulinum Toxin Type A (BoNT-A)
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gerard E FranciscoPhysical Medicine and Rehabilitation, University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX 77030, USA. E-mail: gerard.e.francisco@uth.tmc.edu.
Alexander Balbert
Ganesh Bavikatte
Djamel Bensmail
Stefano Carda
Thierry Deltombe
Nathalie Draulans
Steven Escaldi
Raphael Gross
Jorge Jacinto
Nicholas Ketchum
Franco Molteni
Susana Moraleda
Michael W ODell
Rajiv Reebye
Patrik Säterö
Monica Verduzco-Gutierrez
Heather Walker
Jörg Wissel

Funding

Institutional Career Development CoreKL2TR003168 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, CHARLES C · 2019 to 2023
$4.9M
6 · The paper itself

Abstract

This consensus paper is derived from a meeting of an international group of 19 neurological rehabilitation specialists with a combined experience of more than 250 years (range 4-25 years; mean 14.1 years) in treating post-stroke spasticity with botulinum toxin A. The group undertook critical assessments of some recurring practical challenges, not yet addressed in guidelines, through an exten-sive literature search. They then discussed the results in the light of their individual clinical experience and developed consensus statements to present to the wider community who treat such patients. The analysis provides a comprehensive overview of treatment with botulinum toxin A, including the use of adjunctive therapies, within a multidisciplinary context, and is aimed at practicing clinicians who treat patients with post-stroke spasticity and require further practical guidance on the use of botulinum toxin A. This paper does not replicate information published elsewhere, but instead aims to provide practical advice to help optimize the use of botulinum toxin A and maximize clinical outcomes. The recommendations for each topic are summarized in a series of statements. Where published high-quality evidence exists, the recommendations reflect this. However, where evidence is not yet conclusive, the group members issued statements and, in some cas-es, made recommendations based on their clinical experience.

Indexed as

Botulinum Toxins, Type AHumansMuscle SpasticityNeuromuscular AgentsStrokeBotulinum Toxins, Type ANeuromuscular Agentsbotulinum toxinconsensus guidelinespasticity

Identifiers

PMID33057730
PMCPMC8772370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.